Antimicrobial treatment and clinical outcomes of carbapenem-resistant acinetobacter baumannii ventilator-associated pneumonia

Journal of Intensive Care Medicine

Volumn 25, Issue 6, 2010, Pages 343-348

  Chan, Jeannie D ^a   Graves, Joseph A ^b   Dellit, Timothy H ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

carbapenem resistant Acinetobacter; outcomes; treatment; ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; CEFEPIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; CREATININE; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; NAFCILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; SERRATIA INFECTION; SPUTUM CULTURE; STAPHYLOCOCCUS INFECTION; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650271646     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066610377975     Document Type: Article

References (22)

1. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 ; 171 (4). 388-416.
2. Kollef KE, Schramm GE, Willis AR, Reichley RM, Micek ST, Kollef MH Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest. 2008 ; 134 (2). 281-287.
3. Maragakis LL, Perl TM Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008 ; 46 (8). 1254-1263.
4. Falagas ME, Kasiakou SK Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 ; 40 (9). 1333-1341.
5. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med. 2003 ; 29 (11). 2072-2076.
6. Karageorgopoulos DE, Kelesidis T., Kelesidis I., Falagas ME Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother. 2008 ; 62 (1). 45-55.
7. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002 ; 34 (11). 1425-1430.
8. Betrosian AP, Frantzeskaki F., Xanthaki A., Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J of Infect Dis. 2007 ; 39 (1). 38-43.
9. Betrosian AP, Frantzeskaki F., Xanthaki A., Douzinas EE Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as mono-therapy for the treatment of multidrug resistant. Acinetobacter baumannii. ventilator-associated pneumonia. J Infect. 2008 ; 56 (6). 432-436.
10. Garnacho-Montero J., Ortiz-Leyba C., Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003 ; 36 (9). 1111-1118.
11. Pintado V., San Miguel LG, Grill F., et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect. 2008 ; 56 (3). 185-190.
12. Reina R., Estenssoro E., Saenz G., et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005 ; 31 (8). 1058-1065.
13. Kallel H., Hergafi L., Bahloul M., et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007 ; 33 (7). 1162-1167.
14. Levin AS, Barone AA, Penco J., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999 ; 28 (5). 1008-1011.
15. Jeffres MN, Isakow W., Doherty JA, Micek ST, Kollef MH A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care associated methicillinresistant Staphylococcus aureus pneumonia. Clin Ther. 2007 ; 29 (6). 1107-1115.
16. Lodise TP, Lomaestro B., Graves J., Drusano GL Larger vancomycin doses (at least four gram per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008 ; 52 (4). 1330-1336.
17. Koch-Weser J., Sidel VW, Federman EB, Kanarek P., Finer DC, Eaten AE Adverse effects of sodium colistimethate -manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970 ; 72 (6). 857-868.
18. Baines RD Jr Rifkind, D. Intravenous administration of sodium colistimethate. JAMA. 1964 ; 190: 278-281.
19. Price DJE, Graham DI Effects of large doses of colistin sulfomethate on renal function. Br Med J. 1970 ; 4 (5734). 525-527.
20. Markou N., Apostolakos H., Koumoudiou C., et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003 ; 7 (5). R78 - R83.
21. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G., Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2006 ; 25 (9). 596-599.
22. Harzell JD, Neff R., Ake J., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009; 48 (12). 1724-1728.